What are the common virulence genes of uropathogenic Escherichia coli (UPEC)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Common Virulence Genes of UPEC

The most common virulence genes in uropathogenic E. coli (UPEC) include fimH (type 1 fimbriae), iron acquisition genes (fyuA, iutA, aerobactin), adhesin genes (pap, sfa/foc), and protectin genes (kpsMT, traT), with fimH being the most prevalent at 68-90% of isolates.

Major Categories of UPEC Virulence Genes

Adhesins (Most Critical for Pathogenesis)

  • fimH (type 1 fimbriae): The most prevalent virulence gene, detected in 58-90% of UPEC strains, encoding mannose-sensitive adhesins that mediate initial bladder colonization 1, 2

  • pap (pyelonephritis-associated pili): Present in 20-41% of isolates, encoding P fimbriae that facilitate kidney infection and ascending UTI 3, 2

  • sfa/foc (S and F1C fimbriae): Found in 21-34% of strains, contributing to tissue tropism and bacterial persistence 3, 2

  • afa (afimbrial adhesins): Detected in 8-20% of isolates, providing alternative adhesion mechanisms 3, 2

Iron Acquisition Systems (Essential for Bacterial Survival)

  • fyuA (yersiniabactin receptor): Highly prevalent at 70% of UPEC strains, facilitating iron scavenging in iron-limited urinary tract environment 4

  • iutA (aerobactin receptor): Present in 62% of isolates, working synergistically with aerobactin for iron uptake 4

  • aer/aerobactin: Found in 48-56% of strains, encoding siderophore systems critical for bacterial growth in urine 1, 4, 2

Protectins (Immune Evasion)

  • kpsMT (capsule synthesis): Detected in 58-61% of UPEC, encoding polysaccharide capsules that protect against phagocytosis and complement-mediated killing 1, 4

  • traT (serum resistance): Present in 66% of isolates, conferring resistance to serum bactericidal activity 4

Toxins (Tissue Damage)

  • hly (hemolysin): Found in 19-27% of strains, causing host cell lysis and tissue damage 3, 2

  • cnf (cytotoxic necrotizing factor): Detected in only 3% of isolates, inducing cytoskeletal rearrangements 2

  • astA/set (heat-stable enterotoxin): Present in 31% of strains, contributing to inflammatory responses 1

Additional Virulence Factors

  • usp (uropathogenic-specific protein): Highly expressed in 68% of UPEC during infection, though its exact function remains under investigation 1

  • iha (iron-regulated gene homologue adhesin): Expressed in 65% of strains, providing additional adherence capabilities 1

Clinical Implications

The most common virulence pattern involves co-expression of multiple genes (irp2/fim/iha/kpsMT/usp), exhibited by 14.4% of strains, indicating that UPEC pathogenesis requires coordinated action of adhesins, iron acquisition systems, and immune evasion factors 1. These virulence genes are predominantly found in phylogenetic groups B2 (34%) and D (28%), which represent the most pathogenic UPEC lineages 4.

The hemagglutination phenotype (primarily mannose-resistant) was present in 67-75% of isolates, reflecting the functional expression of adhesin genes and their crucial role in establishing infection 3. Importantly, 94% of UPEC strains are multidrug resistant, with virulence genes highly prevalent among antibiotic-resistant isolates, complicating treatment strategies 4.

References

Research

Distribution of uropathogenic virulence genes in Escherichia coli isolated from patients with urinary tract infection.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.